PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21207206-1 2011 The recent publication of the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) has affirmed the important role of aldosterone-receptor antagonism across the spectrum of systolic heart failure. Eplerenone 30-40 nuclear receptor subfamily 3 group C member 2 Homo sapiens 159-179 18084345-0 2008 Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Eplerenone 14-24 nuclear receptor subfamily 3 group C member 2 Homo sapiens 28-54 21190955-5 2011 These changes were abolished by eplerenone (100 mg/kg/d), a mineralocorticoid receptor (MR) antagonist, but unaffected by hydralazine (80 mg/liter in drinking water). Eplerenone 32-42 nuclear receptor subfamily 3 group C member 2 Homo sapiens 60-86 21190955-5 2011 These changes were abolished by eplerenone (100 mg/kg/d), a mineralocorticoid receptor (MR) antagonist, but unaffected by hydralazine (80 mg/liter in drinking water). Eplerenone 32-42 nuclear receptor subfamily 3 group C member 2 Homo sapiens 88-90 21186336-4 2011 However, our preliminary data have indicated that acute administration of aldosterone or a selective MR antagonist, eplerenone, does not change blood pressure, heart rate, or renal blood flow. Eplerenone 116-126 nuclear receptor subfamily 3 group C member 2 Homo sapiens 101-103 18555797-4 2008 When aldosterone-treated HBMEC were incubated with the activated protein C (APC), the partial thromboplastin clotting time (aPTT) increased 2.5-fold over control, from 10 to 25 s. The MCR antagonists aldactone and eplerenone reduced the basal coagulation time in untreated cells to 33.5% and 42% of the control, respectively. Eplerenone 214-224 nuclear receptor subfamily 3 group C member 2 Homo sapiens 184-187 18040710-1 2008 Despite the fact that mineralocorticoid receptor (MR) antagonist drugs such as spironolactone and eplerenone reduce the mortality in heart failure patients, there is, thus far, no unambiguous demonstration of a functional role of MR in cardiac cells. Eplerenone 98-108 nuclear receptor subfamily 3 group C member 2 Homo sapiens 50-52 21731887-6 2011 The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) study added additional evidence to support the expanded use of aldosterone receptor antagonists in heart failure patients. Eplerenone 4-14 nuclear receptor subfamily 3 group C member 2 Homo sapiens 161-181 20535129-3 2010 We have further shown that the elastogenic effect of aldosterone, which can be enhanced in the presence of mineralocorticoid receptor (MR) antagonists spironolactone and eplerenone, is executed in a MR-independent manner via amplification of IGF-I receptor-mediated signaling. Eplerenone 170-180 nuclear receptor subfamily 3 group C member 2 Homo sapiens 135-137 20535129-3 2010 We have further shown that the elastogenic effect of aldosterone, which can be enhanced in the presence of mineralocorticoid receptor (MR) antagonists spironolactone and eplerenone, is executed in a MR-independent manner via amplification of IGF-I receptor-mediated signaling. Eplerenone 170-180 nuclear receptor subfamily 3 group C member 2 Homo sapiens 199-201 20625290-2 2010 RECENT FINDINGS: Recent studies in animal models of CKD demonstrate that blockade of the mineralocorticoid receptor using spironolactone or eplerenone decreases inflammation, oxidative stress, proteinuria and glomerular and tubular injury. Eplerenone 140-150 nuclear receptor subfamily 3 group C member 2 Homo sapiens 89-115 18585409-8 2008 IN CONCLUSION: a) eplerenone inhibits the intracrine action of Ang II on inward calcium current and reduces drastically the effect of extracellular Ang II on I(Ca); b) aldosterone is able to revert the effect of eplerenone; c) the mineralocorticoid receptor is an essential component of the intracrine renin angiotensin aldosterone system. Eplerenone 18-28 nuclear receptor subfamily 3 group C member 2 Homo sapiens 231-257 18585409-8 2008 IN CONCLUSION: a) eplerenone inhibits the intracrine action of Ang II on inward calcium current and reduces drastically the effect of extracellular Ang II on I(Ca); b) aldosterone is able to revert the effect of eplerenone; c) the mineralocorticoid receptor is an essential component of the intracrine renin angiotensin aldosterone system. Eplerenone 212-222 nuclear receptor subfamily 3 group C member 2 Homo sapiens 231-257 18729003-3 2008 The mineralocorticoid receptor (MR) antagonists spironolactone and eplerenone reduce morbidity and mortality, and it has been suggested that this occurs, in part, as a result of improved vascular function. Eplerenone 67-77 nuclear receptor subfamily 3 group C member 2 Homo sapiens 4-30 18729003-3 2008 The mineralocorticoid receptor (MR) antagonists spironolactone and eplerenone reduce morbidity and mortality, and it has been suggested that this occurs, in part, as a result of improved vascular function. Eplerenone 67-77 nuclear receptor subfamily 3 group C member 2 Homo sapiens 32-34 18084345-4 2008 Eplerenone, a mineralocorticoid-receptor antagonist with minimal binding to the progesterone and androgen receptors, is now licensed for treatment of heart failure in Europe and heart failure and hypertension in the US; it has also been proposed as a treatment for a variety of cardiovascular conditions. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 14-40 19804189-0 2006 Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 62-88 17596522-4 2007 The EMT was completely blocked by the selective mineralocorticoid receptor (MR) antagonist eplerenone. Eplerenone 91-101 nuclear receptor subfamily 3 group C member 2 Homo sapiens 48-74 17596522-4 2007 The EMT was completely blocked by the selective mineralocorticoid receptor (MR) antagonist eplerenone. Eplerenone 91-101 nuclear receptor subfamily 3 group C member 2 Homo sapiens 76-78 17645055-4 2007 In addition, a novel mineralocorticoid receptor antagonist has been developped, named eplerenone, which lack the side effect of former ARMs as gynecomastia. Eplerenone 86-96 nuclear receptor subfamily 3 group C member 2 Homo sapiens 21-47 17827916-12 2007 Pretreatment with either eplerenone or okadaic acid restored phosphorylation levels of eNOS Ser 1177 in aldosterone-treated cells, suggesting that protein phosphatase (PP) 2A was upregulated by aldosterone via MR. Eplerenone 25-35 nuclear receptor subfamily 3 group C member 2 Homo sapiens 210-212 17075718-1 2006 Two clinical trials, the Randomized ALdosterone Evaluation Study (RALES) and the EPlerenone HEart failure and SUrvival Study (EPHESUS), have recently shown that mineralocorticoid receptor (MR) antagonists reduce mortality in patients with heart failure on top of ACE inhibition. Eplerenone 81-91 nuclear receptor subfamily 3 group C member 2 Homo sapiens 161-187 17075718-1 2006 Two clinical trials, the Randomized ALdosterone Evaluation Study (RALES) and the EPlerenone HEart failure and SUrvival Study (EPHESUS), have recently shown that mineralocorticoid receptor (MR) antagonists reduce mortality in patients with heart failure on top of ACE inhibition. Eplerenone 81-91 nuclear receptor subfamily 3 group C member 2 Homo sapiens 189-191 15733814-1 2005 Eplerenone is a new aldosterone-receptor blocker that differs from spironolactone by virtue of higher selectivity for the aldosterone receptor. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 122-142 16754797-12 2006 Pretreatment with either eplerenone or okadaic acid restored phosphorylation levels of eNOS Ser 1177 in Aldo-treated cells, suggesting that protein phosphatase 2A was upregulated by Aldo via mineralocorticoid receptor. Eplerenone 25-35 nuclear receptor subfamily 3 group C member 2 Homo sapiens 191-217 16553572-7 2006 For the increasing proportion of patients with primary aldosteronism suitable for long-term medical treatment, mineralocorticoid receptor blockade (better tolerated with eplerenone) should be considered the most appropriate choice of treatment, pending the development of better alternatives. Eplerenone 170-180 nuclear receptor subfamily 3 group C member 2 Homo sapiens 111-137 16366159-17 2005 Data on a selective aldosterone receptor antagonist, eplerenone, appear promising for the effective blockade of aldosterone and its harmful effects without the sexual disturbances of spironolactone. Eplerenone 53-63 nuclear receptor subfamily 3 group C member 2 Homo sapiens 20-40 16101407-5 2005 In addition, we compare the effects of eplerenone and spironolactone, a nonselective aldosterone blocker, on the transcriptional activity of MR and provide a molecular explanation for the improved side-effect profile of eplerenone compared with spironolactone. Eplerenone 39-49 nuclear receptor subfamily 3 group C member 2 Homo sapiens 141-143 16101407-5 2005 In addition, we compare the effects of eplerenone and spironolactone, a nonselective aldosterone blocker, on the transcriptional activity of MR and provide a molecular explanation for the improved side-effect profile of eplerenone compared with spironolactone. Eplerenone 220-230 nuclear receptor subfamily 3 group C member 2 Homo sapiens 141-143 16877339-6 2006 Eplerenone, a specific MR antagonist, inhibited this gene induction by aldosterone in VSMCs. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 23-25 16611048-12 2006 Although eplerenone is 20-fold less potent at the MR, it demonstrates efficacy similar to spironolactone, possibly due to decreased protein binding. Eplerenone 9-19 nuclear receptor subfamily 3 group C member 2 Homo sapiens 50-52 16342656-1 2005 The benefits of aldosterone receptor antagonists (spironolactone and eplerenone) for patients with heart failure were shown in 2 recent randomized controlled trials. Eplerenone 69-79 nuclear receptor subfamily 3 group C member 2 Homo sapiens 16-36 16101407-0 2005 Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Eplerenone 65-75 nuclear receptor subfamily 3 group C member 2 Homo sapiens 24-50 16101407-2 2005 MR activates transcription of target genes upon aldosterone binding, and eplerenone selectively binds to MR and blocks aldosterone- mediated activation. Eplerenone 73-83 nuclear receptor subfamily 3 group C member 2 Homo sapiens 105-107 15761029-8 2005 Interestingly, MR antagonists, such as eplerenone and progesterone, become partial agonist/antagonist of S810L but are still able to recruit LXXLL peptides to the mutant receptor. Eplerenone 39-49 nuclear receptor subfamily 3 group C member 2 Homo sapiens 15-17 15590870-0 2005 Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 24-44 15590870-6 2005 DATA SYNTHESIS: Eplerenone is the first selective aldosterone receptor antagonist. Eplerenone 16-26 nuclear receptor subfamily 3 group C member 2 Homo sapiens 50-70 15860254-2 2005 Animal studies with the selective MR antagonist eplerenone have similarly shown MR blockade to prevent the cerebral, renal and coronary vascular inflammatory response to elevated aldosterone levels. Eplerenone 48-58 nuclear receptor subfamily 3 group C member 2 Homo sapiens 34-36 15860254-2 2005 Animal studies with the selective MR antagonist eplerenone have similarly shown MR blockade to prevent the cerebral, renal and coronary vascular inflammatory response to elevated aldosterone levels. Eplerenone 48-58 nuclear receptor subfamily 3 group C member 2 Homo sapiens 80-82 15257862-2 2004 Spironolactone and eplerenone are the mineralocorticoid receptor (MR) antagonists currently available for the treatment of hypertension. Eplerenone 19-29 nuclear receptor subfamily 3 group C member 2 Homo sapiens 38-64 15554912-0 2004 Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Eplerenone 35-45 nuclear receptor subfamily 3 group C member 2 Homo sapiens 93-119 15554912-1 2004 The importance of mineralocorticoid receptor (MR) antagonists in the treatment of cardiovascular disease has been emphasised by two recent clinical trials, one using spironolactone and the other using a new selective MR antagonist, namely eplerenone. Eplerenone 239-249 nuclear receptor subfamily 3 group C member 2 Homo sapiens 18-44 15554912-1 2004 The importance of mineralocorticoid receptor (MR) antagonists in the treatment of cardiovascular disease has been emphasised by two recent clinical trials, one using spironolactone and the other using a new selective MR antagonist, namely eplerenone. Eplerenone 239-249 nuclear receptor subfamily 3 group C member 2 Homo sapiens 46-48 15554912-1 2004 The importance of mineralocorticoid receptor (MR) antagonists in the treatment of cardiovascular disease has been emphasised by two recent clinical trials, one using spironolactone and the other using a new selective MR antagonist, namely eplerenone. Eplerenone 239-249 nuclear receptor subfamily 3 group C member 2 Homo sapiens 217-219 15554912-3 2004 Determinants of binding specificity of eplerenone to the MR were investigated using chimeras created between the ligand-binding domains (LBD) of the MR and the GR. Eplerenone 39-49 nuclear receptor subfamily 3 group C member 2 Homo sapiens 57-59 15554912-3 2004 Determinants of binding specificity of eplerenone to the MR were investigated using chimeras created between the ligand-binding domains (LBD) of the MR and the GR. Eplerenone 39-49 nuclear receptor subfamily 3 group C member 2 Homo sapiens 149-151 15554912-5 2004 Eplerenone competed strongly for [(3)H]-dexamethasone binding to a MR/GR chimera containing amino acids 804-874 of the MR and weakly to a chimera containing amino acids 672-803 of the MR. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 67-69 15554912-5 2004 Eplerenone competed strongly for [(3)H]-dexamethasone binding to a MR/GR chimera containing amino acids 804-874 of the MR and weakly to a chimera containing amino acids 672-803 of the MR. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 119-121 15554912-5 2004 Eplerenone competed strongly for [(3)H]-dexamethasone binding to a MR/GR chimera containing amino acids 804-874 of the MR and weakly to a chimera containing amino acids 672-803 of the MR. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 119-121 15554912-6 2004 Within the 804-874 region, eplerenone competed for [(3)H]-dexamethasone binding to a chimera containing amino acids 820-844 of the MR, although the calculated affinity was approximately 10-fold lower than for binding to the full-length MR LBD. Eplerenone 27-37 nuclear receptor subfamily 3 group C member 2 Homo sapiens 131-133 15554912-6 2004 Within the 804-874 region, eplerenone competed for [(3)H]-dexamethasone binding to a chimera containing amino acids 820-844 of the MR, although the calculated affinity was approximately 10-fold lower than for binding to the full-length MR LBD. Eplerenone 27-37 nuclear receptor subfamily 3 group C member 2 Homo sapiens 236-238 15554912-8 2004 Modelling of eplerenone binding to the MR LBD, based on the GR LBD crystal structure, suggests that amino acids 820-844 affect the overall shape of the ligand-binding pocket and that eplerenone acts as an MR antagonist because it fails to stabilize the active conformation of the receptor. Eplerenone 13-23 nuclear receptor subfamily 3 group C member 2 Homo sapiens 39-41 15554912-8 2004 Modelling of eplerenone binding to the MR LBD, based on the GR LBD crystal structure, suggests that amino acids 820-844 affect the overall shape of the ligand-binding pocket and that eplerenone acts as an MR antagonist because it fails to stabilize the active conformation of the receptor. Eplerenone 183-193 nuclear receptor subfamily 3 group C member 2 Homo sapiens 39-41 15554912-8 2004 Modelling of eplerenone binding to the MR LBD, based on the GR LBD crystal structure, suggests that amino acids 820-844 affect the overall shape of the ligand-binding pocket and that eplerenone acts as an MR antagonist because it fails to stabilize the active conformation of the receptor. Eplerenone 183-193 nuclear receptor subfamily 3 group C member 2 Homo sapiens 205-207 15257862-2 2004 Spironolactone and eplerenone are the mineralocorticoid receptor (MR) antagonists currently available for the treatment of hypertension. Eplerenone 19-29 nuclear receptor subfamily 3 group C member 2 Homo sapiens 66-68 15182600-6 2004 One may therefore hypothesize that MR antagonism with eplerenone may be beneficial in patients with ACS. Eplerenone 54-64 nuclear receptor subfamily 3 group C member 2 Homo sapiens 35-37 16036025-1 2004 Results of the Randomized Aldactone Evaluation Study and the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study indicate aldosterone receptor antagonism, together with angiotensin-converting enzyme inhibition and loop diuretics, is a most effective strategy in reducing risk for all-cause and cardiovascular-related mortality and morbidity in patients with symptomatic heart failure. Eplerenone 61-71 nuclear receptor subfamily 3 group C member 2 Homo sapiens 156-176 15182600-7 2004 Another advantage of using eplerenone is that it offers the advantages of MR antagonism without the side effects due to blockade of other nuclear receptors such as the androgen and progesterone receptors. Eplerenone 27-37 nuclear receptor subfamily 3 group C member 2 Homo sapiens 74-76 14640940-3 2003 Over the past 5 years, mineralocorticoid receptor (MR) antagonists have been used in two major outcome trials (the Randomized Aldactone Evaluation Study [RALES] with spironolactone, and the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study [EPHESUS]), in severe (New York Heart Association class III) and post-myocardial infarct heart failure, respectively. Eplerenone 190-200 nuclear receptor subfamily 3 group C member 2 Homo sapiens 23-49 15349128-3 2004 The side-effect profile indicates that the specificity of eplerenone for the mineralocorticoid receptor is responsible for the lower incidence of sex hormone- related side-effects than have been seen with other mineralocorticoid receptor blockers. Eplerenone 58-68 nuclear receptor subfamily 3 group C member 2 Homo sapiens 77-103 15349128-3 2004 The side-effect profile indicates that the specificity of eplerenone for the mineralocorticoid receptor is responsible for the lower incidence of sex hormone- related side-effects than have been seen with other mineralocorticoid receptor blockers. Eplerenone 58-68 nuclear receptor subfamily 3 group C member 2 Homo sapiens 211-237 15181050-1 2004 In two clinical trials on the antihypertensive effects of the mineralocorticoid receptor antagonist eplerenone 397 essential hypertensives were dose titrated (50, 100, and 200 mg/d) over successive 4-wk periods until they reached target blood pressure levels. Eplerenone 100-110 nuclear receptor subfamily 3 group C member 2 Homo sapiens 62-88 16200104-3 2004 Due to the selectivity of eplerenone for the aldosterone receptor, adverse effects such as gynecomastia and vaginal bleeding seem to be less likely in patients who take eplerenone than in those who take spironolactone. Eplerenone 26-36 nuclear receptor subfamily 3 group C member 2 Homo sapiens 45-65 16200104-3 2004 Due to the selectivity of eplerenone for the aldosterone receptor, adverse effects such as gynecomastia and vaginal bleeding seem to be less likely in patients who take eplerenone than in those who take spironolactone. Eplerenone 169-179 nuclear receptor subfamily 3 group C member 2 Homo sapiens 45-65 15128471-5 2004 Eplerenone, which is more specific for the mineralocorticoid receptor, appears to provide all the beneficial effects of spironolactone in hypertensive patients, with the potential to modify many of the side effects related to nonspecific steroid-receptor blockade. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 43-69 15160833-8 2004 Administration of eplerenone, a selective mineralocorticoid receptor antagonist, following induction of ischemic injury in animals, blocked the progressive ventricular dilatation and reduction in systolic function observed in control animals; clinical studies indicate that those findings can be translated to human cardiovascular disease. Eplerenone 18-28 nuclear receptor subfamily 3 group C member 2 Homo sapiens 42-68 14640940-3 2003 Over the past 5 years, mineralocorticoid receptor (MR) antagonists have been used in two major outcome trials (the Randomized Aldactone Evaluation Study [RALES] with spironolactone, and the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study [EPHESUS]), in severe (New York Heart Association class III) and post-myocardial infarct heart failure, respectively. Eplerenone 190-200 nuclear receptor subfamily 3 group C member 2 Homo sapiens 51-53 14640940-4 2003 Experimental studies have largely focused, however, on various animal models of hypertension; on the basis of a portfolio of clinical studies on the efficacy of eplerenone, administered either alone and in combination as an antihypertensive agent, the novel MR antagonist was approved by the FDA for the treatment of hypertension, though it has yet to be launched. Eplerenone 161-171 nuclear receptor subfamily 3 group C member 2 Homo sapiens 258-260 12914736-7 2003 Eplerenone is a new competitive and selective aldosterone receptor antagonist recently approved by the United States Food and Drug Administration for the treatment of hypertension. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 46-66 12555163-4 2002 Further proof of this hypothesis should be forthcoming from the results of the Eplerenone Heart Failure Efficacy and Survival Study (EPHESUS) early in 2003 in which the aldosterone receptor antagonist eplerenone is being evaluated in patients with systolic left ventricular dysfunction post myocardial infarction. Eplerenone 201-211 nuclear receptor subfamily 3 group C member 2 Homo sapiens 169-189 12962513-5 2003 Eplerenone is the first selective aldosterone receptor antagonist to be developed and recently gained approval from the US FDA for treatment of systemic hypertension. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 34-54 12624573-0 2003 Aldosterone receptor antagonists: focus on eplerenone. Eplerenone 43-53 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-20 12624573-6 2003 Eplerenone, a new selective aldosterone receptor antagonist, recently received approval from the US Food and Drug Administration for the treatment of hypertension, either alone or in combination with other antihypertensive agents. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 28-48 10760075-10 2000 Eplerenone is a competitive antagonist of the mineralocorticoid receptor that takes advantage of replacing the 17alpha-thoacetyl group of spironolactone with a carbomethoxy group, conferring excellent selectivity for the mineralocorticoid receptor over other steroid receptors. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 46-72 12431020-3 2002 Emerging evidence from an extensive development program for eplerenone (Pharmacia Corp), a novel selective aldosterone receptor antagonist, may further expand the evidence base for aldosterone receptor antagonism, including its potential in treating hypertension. Eplerenone 60-70 nuclear receptor subfamily 3 group C member 2 Homo sapiens 107-127 12431020-3 2002 Emerging evidence from an extensive development program for eplerenone (Pharmacia Corp), a novel selective aldosterone receptor antagonist, may further expand the evidence base for aldosterone receptor antagonism, including its potential in treating hypertension. Eplerenone 60-70 nuclear receptor subfamily 3 group C member 2 Homo sapiens 181-201 10760075-10 2000 Eplerenone is a competitive antagonist of the mineralocorticoid receptor that takes advantage of replacing the 17alpha-thoacetyl group of spironolactone with a carbomethoxy group, conferring excellent selectivity for the mineralocorticoid receptor over other steroid receptors. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 221-247 10760075-11 2000 The pharmacological profile of eplerenone positions it to be an effective and selective mineralocorticoid receptor antagonist. Eplerenone 31-41 nuclear receptor subfamily 3 group C member 2 Homo sapiens 88-114 33904521-3 2021 It is designed to determine if participants with the STRN risk alleles will have a greater BP reduction on a liberal salt diet with a specific, mechanism-based therapy - a mineralocorticoid receptor antagonist, eplerenone - as compared with a nonspecific anti-hypertensive therapy - amlodipine. Eplerenone 211-221 nuclear receptor subfamily 3 group C member 2 Homo sapiens 172-198 34595995-2 2021 However, RH often goes untreated in this population as the currently available recommended add-on therapy, steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone, may lead to unacceptable side effects, mainly hyperkalemia in a cohort with reduced kidney function. Eplerenone 190-200 nuclear receptor subfamily 3 group C member 2 Homo sapiens 117-143 34272676-2 2021 The mineralocorticoid receptor antagonist (MRA) eplerenone prevents left ventricular (LV) remodeling in patients with acute myocardial infarction, but its influence on cardiac sympathetic nerve activity (CSNA) has not been determined. Eplerenone 48-58 nuclear receptor subfamily 3 group C member 2 Homo sapiens 4-30 34790127-4 2021 Clinical studies demonstrated the usefulness of MR antagonists (MRAs), such as spironolactone and eplerenone, on DKD. Eplerenone 98-108 nuclear receptor subfamily 3 group C member 2 Homo sapiens 48-50 34461222-5 2021 The second steroidal MR antagonist was eplerenone which was discovered at a time when the role of aldosterone and MR in cardiac fibrosis was rediscovered. Eplerenone 39-49 nuclear receptor subfamily 3 group C member 2 Homo sapiens 21-23 34205363-3 2021 To reduce morbidity and mortality in advanced stage HF, MR antagonist drugs, such as spironolactone and eplerenone, are used. Eplerenone 104-114 nuclear receptor subfamily 3 group C member 2 Homo sapiens 56-58 34983084-2 2022 Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist that used primarily to treat hypertension. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 32-58 34233330-4 2021 The antiproteinuric effect of mineralocorticoid receptor antagonists (spironolactone, eplerenone, and finerenone) has been clearly established through prospective and controlled studies, and treatment with finerenone reduces the risk of chronic kidney disease progression in type-2 diabetic patients. Eplerenone 86-96 nuclear receptor subfamily 3 group C member 2 Homo sapiens 30-56 34983084-2 2022 Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist that used primarily to treat hypertension. Eplerenone 12-15 nuclear receptor subfamily 3 group C member 2 Homo sapiens 32-58 35607563-2 2022 The main cause of PA is bilateral adrenal hyperplasia, and treatment is usually medical with mineralocorticoid receptor antagonists (MRAs) such as spironolactone or eplerenone. Eplerenone 165-175 nuclear receptor subfamily 3 group C member 2 Homo sapiens 93-119 35582468-5 2022 AIM: To investigate potential differences between finerenone and eplerenone at engaging GRK5-dependent cardiac MR phosphorylation and subsequent blockade. Eplerenone 65-75 nuclear receptor subfamily 3 group C member 2 Homo sapiens 111-113 35582468-8 2022 Unlike eplerenone, finerenone alone potently and efficiently suppresses cardiac MR transcriptional activity, thus displaying inverse agonism. Eplerenone 7-17 nuclear receptor subfamily 3 group C member 2 Homo sapiens 80-82 32661269-1 2021 The steroidal mineralocorticoid receptor (MR) antagonists, spironolactone and eplerenone, decrease blood pressure, and attenuate the progression of chronic kidney disease (CKD). Eplerenone 78-88 nuclear receptor subfamily 3 group C member 2 Homo sapiens 14-40 32473789-2 2021 Blockade of the biological effects of aldosterone has mostly been achieved with spironolactone and eplerenone, the two steroidal MR antagonists currently on the market. Eplerenone 99-109 nuclear receptor subfamily 3 group C member 2 Homo sapiens 129-131 33179798-1 2021 Mineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension. Eplerenone 77-87 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 33179798-1 2021 Mineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension. Eplerenone 77-87 nuclear receptor subfamily 3 group C member 2 Homo sapiens 28-30 33995571-3 2021 Eplerenone is a selective mineralocorticoid receptor antagonist that does not act as an androgen receptor blocker, thus reducing the risk of fetal anti-androgenic effects. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 26-52 32661269-1 2021 The steroidal mineralocorticoid receptor (MR) antagonists, spironolactone and eplerenone, decrease blood pressure, and attenuate the progression of chronic kidney disease (CKD). Eplerenone 78-88 nuclear receptor subfamily 3 group C member 2 Homo sapiens 42-44 31079056-1 2020 BACKGROUND/AIMS: The efficacy of mineralocorticoid receptor antagonist eplerenone to treat chronic central serous chorioretinopathy (CSCR) has been established. Eplerenone 71-81 nuclear receptor subfamily 3 group C member 2 Homo sapiens 33-59 33055188-0 2021 The Mineralocorticoid Receptor Antagonist Eplerenone Suppress Interstitial Fibrosis in Subcutaneous Adipose Tissue in Type 2 Diabetes Patients. Eplerenone 42-52 nuclear receptor subfamily 3 group C member 2 Homo sapiens 4-30 33082868-4 2020 In the present study, eplerenone (EPL), a mineralocorticoid receptor antagonist, was first doped with Gd2O3 nanoparticles (Gd2O3-EPL), following which its diagnostic efficacy for use in IVUS measurements (Gd2O3-EPL-IVUS) was evaluated for patients suspected with atherosclerosis. Eplerenone 22-32 nuclear receptor subfamily 3 group C member 2 Homo sapiens 42-68 33082868-4 2020 In the present study, eplerenone (EPL), a mineralocorticoid receptor antagonist, was first doped with Gd2O3 nanoparticles (Gd2O3-EPL), following which its diagnostic efficacy for use in IVUS measurements (Gd2O3-EPL-IVUS) was evaluated for patients suspected with atherosclerosis. Eplerenone 34-37 nuclear receptor subfamily 3 group C member 2 Homo sapiens 42-68 32799671-2 2021 A vast number of studies that has demonstrated the role of mineralocorticoids in cardiovascular diseases is based on the use of pharmacological mineralocorticoid receptor antagonists (MRA) such as spironolactone and eplerenone. Eplerenone 216-226 nuclear receptor subfamily 3 group C member 2 Homo sapiens 144-170 32973172-4 2020 These ALD-induced changes were blocked by applying the mineralocorticoid receptor antagonist eplerenone. Eplerenone 93-103 nuclear receptor subfamily 3 group C member 2 Homo sapiens 55-81 32128854-3 2020 Further involvement of the MR is supported by extensive animal model experiments where MR antagonists (such as spironolactone and eplerenone) abrogate renal injury, including ischaemia-induced damage. Eplerenone 130-140 nuclear receptor subfamily 3 group C member 2 Homo sapiens 27-29 32128854-3 2020 Further involvement of the MR is supported by extensive animal model experiments where MR antagonists (such as spironolactone and eplerenone) abrogate renal injury, including ischaemia-induced damage. Eplerenone 130-140 nuclear receptor subfamily 3 group C member 2 Homo sapiens 87-89 30280597-6 2018 The effects of exogenous aldosterone and of mineralocorticoid receptor (MR) antagonist eplerenone were determined. Eplerenone 87-97 nuclear receptor subfamily 3 group C member 2 Homo sapiens 72-74 31183945-0 2019 Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial). Eplerenone 52-62 nuclear receptor subfamily 3 group C member 2 Homo sapiens 14-40 31183945-1 2019 AIM: To investigate whether the mineralocorticoid receptor antagonist eplerenone has beneficial effects on liver fat and metabolism in patients with type 2 diabetes (T2D), the mineralocorticoid receptor antagonist in type 2 diabetes (MIRAD) trial. Eplerenone 70-80 nuclear receptor subfamily 3 group C member 2 Homo sapiens 32-58 30444201-5 2019 Presently mineralocorticoid receptor antagonists such as spironolactone, eplerenone and finerenone are being investigated as both monotherapies and as additional therapies. Eplerenone 73-83 nuclear receptor subfamily 3 group C member 2 Homo sapiens 10-36 30444201-7 2019 The commonly observed adverse effects are hyperkalemia, gynaecomastia and vaginal bleeding, that are bothersome with spironolactone seems to be avoidable if these patients are switched to non-steroidal and mineralocorticoid receptor antagonists such as finerenone and eplerenone. Eplerenone 268-278 nuclear receptor subfamily 3 group C member 2 Homo sapiens 206-232 30678854-1 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Eplerenone 63-73 nuclear receptor subfamily 3 group C member 2 Homo sapiens 4-30 31014765-1 2019 TOPIC: A meta-analysis comparing mineralocorticoid receptor (MR) antagonists (eplerenone or spironolactone) versus observation or placebo in the treatment of central serous chorioretinopathy (CSCR) based on best-corrected visual acuity (BCVA) and subretinal fluid (SRF) level data from randomized controlled trials (RCTs). Eplerenone 78-88 nuclear receptor subfamily 3 group C member 2 Homo sapiens 33-59 31014765-1 2019 TOPIC: A meta-analysis comparing mineralocorticoid receptor (MR) antagonists (eplerenone or spironolactone) versus observation or placebo in the treatment of central serous chorioretinopathy (CSCR) based on best-corrected visual acuity (BCVA) and subretinal fluid (SRF) level data from randomized controlled trials (RCTs). Eplerenone 78-88 nuclear receptor subfamily 3 group C member 2 Homo sapiens 61-63 31522177-5 2019 Moreover, the selective MR antagonist eplerenone promoted hair shaft elongation and hair matrix keratinocyte proliferation whilst delaying catagen (HF regression). Eplerenone 38-48 nuclear receptor subfamily 3 group C member 2 Homo sapiens 24-26 29659888-15 2018 MR antagonism with eplerenone was well tolerated among the HIV population, with no considerable changes in blood pressure or potassium. Eplerenone 19-29 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-2 30275698-0 2018 Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses. Eplerenone 69-79 nuclear receptor subfamily 3 group C member 2 Homo sapiens 31-57 30275698-2 2018 Eplerenone, a selective mineralocorticoid receptor antagonist, is an approved treatment option for the management of patients with hypertension in a number of countries. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 24-50 30056252-6 2018 Both Spironolactone and eplerenone significantly increased endothelial arginine transport, an effect which was further augmented by co-incubation with aldosterone, and blunted by either silencing of MCR or co-administration of amiloride. Eplerenone 24-34 nuclear receptor subfamily 3 group C member 2 Homo sapiens 199-202 29622372-0 2018 Treatment of Unruptured Cerebral Aneurysms with the Mineralocorticoid Receptor Blocker Eplerenone-Pilot Study. Eplerenone 87-97 nuclear receptor subfamily 3 group C member 2 Homo sapiens 52-78 28824029-1 2017 BACKGROUND: The mineralocorticoid receptor antagonist eplerenone improved clinical outcomes among patients with heart failure with reduced ejection faction (HFrEF) in the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. Eplerenone 54-64 nuclear receptor subfamily 3 group C member 2 Homo sapiens 16-42 28824029-1 2017 BACKGROUND: The mineralocorticoid receptor antagonist eplerenone improved clinical outcomes among patients with heart failure with reduced ejection faction (HFrEF) in the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. Eplerenone 184-194 nuclear receptor subfamily 3 group C member 2 Homo sapiens 16-42 26644241-5 2016 To test this hypothesis, we determined the acute effects of the mineralocorticoid receptor antagonist eplerenone (50 mg, oral) versus placebo on supine blood pressure in a randomized, double-blind, crossover study. Eplerenone 102-112 nuclear receptor subfamily 3 group C member 2 Homo sapiens 64-90 29121365-2 2017 The authors report an efficient combination therapy of oral mineralocorticoid receptor antagonists (eplerenone [Inspra; Pfizer, New York City, NY] or spironolactone, 25 mg/day to 50 mg/day) and topical dexamethasone (four times/day and progressive dose tapering) in three refractory cases following complex cataract or retinal detachment surgery. Eplerenone 100-110 nuclear receptor subfamily 3 group C member 2 Homo sapiens 60-86 28634268-4 2017 The salient example is eplerenone, first described in 1987, coincidentally with the cloning of MR cDNA. Eplerenone 23-33 nuclear receptor subfamily 3 group C member 2 Homo sapiens 95-97 28011746-11 2017 Similarly, the mineralocorticoid receptor antagonist eplerenone produces acute hypotensive effects, highlighting the presence of non-nuclear mineralocorticoid receptor pathways. Eplerenone 53-63 nuclear receptor subfamily 3 group C member 2 Homo sapiens 15-41 27115525-4 2016 Spironolactone and eplerenone were the first steroidal mineralocorticoid receptor antagonist. Eplerenone 19-29 nuclear receptor subfamily 3 group C member 2 Homo sapiens 55-81 29274772-1 2017 Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone have an established role in the treatment of heart failure. Eplerenone 74-84 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 28515448-3 2017 We show that even in absence of exogenous aldosterone, silencing and pharmacological inhibition (spironolactone, eplerenone) of the mineralocorticoid receptor (MR) ameliorated phosphate-induced osteo-/chondrogenic transformation of primary human aortic smooth muscle cells (HAoSMCs). Eplerenone 113-123 nuclear receptor subfamily 3 group C member 2 Homo sapiens 132-158 28515448-3 2017 We show that even in absence of exogenous aldosterone, silencing and pharmacological inhibition (spironolactone, eplerenone) of the mineralocorticoid receptor (MR) ameliorated phosphate-induced osteo-/chondrogenic transformation of primary human aortic smooth muscle cells (HAoSMCs). Eplerenone 113-123 nuclear receptor subfamily 3 group C member 2 Homo sapiens 160-162 28011746-11 2017 Similarly, the mineralocorticoid receptor antagonist eplerenone produces acute hypotensive effects, highlighting the presence of non-nuclear mineralocorticoid receptor pathways. Eplerenone 53-63 nuclear receptor subfamily 3 group C member 2 Homo sapiens 141-167 27503378-8 2016 Treatment with the mineralocorticoid receptor (MR) antagonist eplerenone inhibited VSMC calcification. Eplerenone 62-72 nuclear receptor subfamily 3 group C member 2 Homo sapiens 19-45 27503378-8 2016 Treatment with the mineralocorticoid receptor (MR) antagonist eplerenone inhibited VSMC calcification. Eplerenone 62-72 nuclear receptor subfamily 3 group C member 2 Homo sapiens 47-49 27664711-4 2016 Indeed, according to Nguyen et al., local inhibition of the mineralocorticoid receptor via antagonists (spironolactone, canrenoate, and eplerenone) rescues GC-induced delayed epithelialization and accelerates wound closure in diabetic animals by targeting epithelial sodium channels and stimulating keratinocyte proliferation. Eplerenone 136-146 nuclear receptor subfamily 3 group C member 2 Homo sapiens 60-86 27680666-6 2016 MR blockade with eplerenone significantly decreased glycemia (P<0.01), total cholesterol (P<0.05), resistin (P<0.05), and described enzymes, with no effect on insulin or triglycerides. Eplerenone 17-27 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-2 26644241-9 2016 These findings suggest that inappropriate mineralocorticoid receptor activation contributes to the hypertension of autonomic failure, likely independent of canonical mineralocorticoid effects, and provides rationale for use of eplerenone in these patients. Eplerenone 227-237 nuclear receptor subfamily 3 group C member 2 Homo sapiens 42-68 28956026-8 2016 Blocking MR using the selective MR antagonist eplerenone can reduce pain and sensory neuron excitability in experimental models of low back pain. Eplerenone 46-56 nuclear receptor subfamily 3 group C member 2 Homo sapiens 9-11 26639352-5 2016 The primary objective of this study was to examine whether acute inhibition of MR by the selective antagonist eplerenone, influences vascular function in healthy older adults. Eplerenone 110-120 nuclear receptor subfamily 3 group C member 2 Homo sapiens 79-81 26639352-8 2016 In response to acute MR antagonism, flow-mediated dilation decreased by 19% (from 6.9+-0.5 to 5.6+-0.6%, P=0.02; placebo vs. eplerenone). Eplerenone 125-135 nuclear receptor subfamily 3 group C member 2 Homo sapiens 21-23 28956026-8 2016 Blocking MR using the selective MR antagonist eplerenone can reduce pain and sensory neuron excitability in experimental models of low back pain. Eplerenone 46-56 nuclear receptor subfamily 3 group C member 2 Homo sapiens 32-34 24713303-2 2014 We report here that pharmacologic inhibition of MR function with eplerenone resulted in increased bone mass, with stimulation of bone formation and suppression of resorption, while specific genetic deletion of MR in osteoblast lineage cells had no effect. Eplerenone 65-75 nuclear receptor subfamily 3 group C member 2 Homo sapiens 48-50 26404746-0 2015 Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone. Eplerenone 120-130 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 26404746-3 2015 These problems can be overcome with use of eplerenone, a selective mineralocorticoid receptor antagonist. Eplerenone 43-53 nuclear receptor subfamily 3 group C member 2 Homo sapiens 67-93 26404747-2 2015 Since a growing medical literature has suggested that mineralocorticoid receptor antagonists may be beneficial for patients with HFpEF, this review gives an in-depth update on the role of spironolactone and eplerenone and their implications for therapy in the setting of HFpEF. Eplerenone 207-217 nuclear receptor subfamily 3 group C member 2 Homo sapiens 54-80 26404747-10 2015 In conclusion although the mineralocorticoid receptor antagonists eplerenone and spironolactone improve clinical outcomes in patients with HFrEF, additional data will be necessary to better define their risk-benefit profile, especially for eplerenone, in the treatment of HFpEF. Eplerenone 66-76 nuclear receptor subfamily 3 group C member 2 Homo sapiens 27-53 26404748-0 2015 Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Eplerenone 77-87 nuclear receptor subfamily 3 group C member 2 Homo sapiens 18-44 26404748-1 2015 Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more mineralocorticoid receptor-specific. Eplerenone 166-176 nuclear receptor subfamily 3 group C member 2 Homo sapiens 213-239 26404748-6 2015 Due to the selectivity of eplerenone for the aldosterone receptor, severe adverse effects such as gynecomastia and vaginal bleeding seem to be less likely in patients who take eplerenone than in those who take spironolactone. Eplerenone 26-36 nuclear receptor subfamily 3 group C member 2 Homo sapiens 45-65 26404748-6 2015 Due to the selectivity of eplerenone for the aldosterone receptor, severe adverse effects such as gynecomastia and vaginal bleeding seem to be less likely in patients who take eplerenone than in those who take spironolactone. Eplerenone 176-186 nuclear receptor subfamily 3 group C member 2 Homo sapiens 45-65 27057293-1 2015 Spironolactone and eplerenone are both mineralocorticoid-receptor antagonists. Eplerenone 19-29 nuclear receptor subfamily 3 group C member 2 Homo sapiens 39-65 26213109-6 2015 Eplerenone is less potent than spironolactone, but causes fewer adverse effects due to its selectivity for the MR. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 111-113 28834677-1 2015 AIMS: The selective mineralocorticoid receptor (MR) antagonist eplerenone given early in patients with acute myocardial infarction (MI) improves clinical outcome, whereas little is known about the effectiveness of early spironolactone therapy. Eplerenone 63-73 nuclear receptor subfamily 3 group C member 2 Homo sapiens 20-46 28834677-1 2015 AIMS: The selective mineralocorticoid receptor (MR) antagonist eplerenone given early in patients with acute myocardial infarction (MI) improves clinical outcome, whereas little is known about the effectiveness of early spironolactone therapy. Eplerenone 63-73 nuclear receptor subfamily 3 group C member 2 Homo sapiens 48-50 25646700-3 2015 AIM: To investigate whether eplerenone, a specific MR antagonist, ameliorates liver damage in experimental NASH. Eplerenone 28-38 nuclear receptor subfamily 3 group C member 2 Homo sapiens 51-53 25564371-9 2015 Moreover, pharmacological-specific blockade of mineralocorticoid receptor by eplerenone inhibited endothelial cell proliferation in a preclinical model of heart failure (transverse aortic constriction). Eplerenone 77-87 nuclear receptor subfamily 3 group C member 2 Homo sapiens 47-73 26572910-4 2015 Marketed MR antagonists, spironolactone and eplerenone, are also believed to be highly efficacious in treatment of chronic kidney disease in diabetes patients, but is contra-indicated due to the increased risk for hyperkalemia. Eplerenone 44-54 nuclear receptor subfamily 3 group C member 2 Homo sapiens 9-11 25458175-1 2015 OBJECTIVES: This study aimed to evaluate the specific role of the 2 available mineralocorticoid receptor antagonists (MRAs), eplerenone and spironolactone, on the modulation of galectin-3 (Gal-3) and interleukin (IL)-33/ST2 signaling in an experimental model of left ventricular systolic dysfunction after acute myocardial infarction (MI). Eplerenone 125-135 nuclear receptor subfamily 3 group C member 2 Homo sapiens 78-104 24486397-9 2014 In the lack of change in basal mineralocorticoid activity, eplerenone increases markers of alternative activation in a mineralocorticoid receptor-independent manner. Eplerenone 59-69 nuclear receptor subfamily 3 group C member 2 Homo sapiens 119-145 25016400-6 2014 These new compounds, which include the new nonsteroidal mineralocorticoid-receptor antagonists and aldosterone synthase inhibitors, try to maintain adequate efficacy, avoiding the drawbacks of spironolactone and eplerenone. Eplerenone 212-222 nuclear receptor subfamily 3 group C member 2 Homo sapiens 56-82 25016401-2 2014 Although salt restriction is an important component of mitigating the profibrotic effects of MR activation, a growing body of literature has shown that MR antagonists, spironolactone and eplerenone, can reduce proteinuria and blood pressure in patients at all stages of CKD. Eplerenone 187-197 nuclear receptor subfamily 3 group C member 2 Homo sapiens 152-154 23838006-7 2013 Aldosterone stimulated phosphorylation of MAP kinases and increased expression of pro-inflammatory mediators ICAM-1, Cox-2 and PAI-1 in Deltakinase and K1648R cells, effects that were inhibited by eplerenone (mineralocorticoid receptor (MR) blocker). Eplerenone 197-207 nuclear receptor subfamily 3 group C member 2 Homo sapiens 209-235 24493871-3 2014 Spironolactone and eplerenone, both MR antagonists, are the only commercially available compounds targeting directly the actions of aldosterone. Eplerenone 19-29 nuclear receptor subfamily 3 group C member 2 Homo sapiens 36-38 24297687-0 2014 Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eplerenone 181-191 nuclear receptor subfamily 3 group C member 2 Homo sapiens 143-169 23582279-7 2013 Eplerenone, a specific MR antagonist, seems to be effective but it does not control the mineralocorticoid excess. Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 23-25 23888997-1 2013 Mineralocorticoid receptor (MR) activation has been shown to play a deleterious role in the development of heart disease in studies using specific MR antagonists (spironolactone, eplerenone) in both experimental models and patients. Eplerenone 179-189 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 23888997-1 2013 Mineralocorticoid receptor (MR) activation has been shown to play a deleterious role in the development of heart disease in studies using specific MR antagonists (spironolactone, eplerenone) in both experimental models and patients. Eplerenone 179-189 nuclear receptor subfamily 3 group C member 2 Homo sapiens 28-30 23888997-9 2013 Together, the pro-arrhythmic effects of aldosterone and/or MR may explain the highly beneficial effect of MR antagonism, namely a decrease in the incidence of sudden death, observed in the Randomized Aldactone Evaluation Study (RALES) and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) studies. Eplerenone 239-249 nuclear receptor subfamily 3 group C member 2 Homo sapiens 59-61 23888997-9 2013 Together, the pro-arrhythmic effects of aldosterone and/or MR may explain the highly beneficial effect of MR antagonism, namely a decrease in the incidence of sudden death, observed in the Randomized Aldactone Evaluation Study (RALES) and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) studies. Eplerenone 239-249 nuclear receptor subfamily 3 group C member 2 Homo sapiens 106-108 23719402-1 2013 PURPOSE: Based on experimental data showing that central serous chorioretinopathy could result from overactivation of mineralocorticoid receptor pathway in choroid vessels, the authors studied eplerenone, a mineralocorticoid receptor antagonist, as a potential treatment for chronic central serous chorioretinopathy. Eplerenone 193-203 nuclear receptor subfamily 3 group C member 2 Homo sapiens 207-233 24120080-6 2013 Pre-treatment with eplerenone (10(-10)M) prevented the increased expression of MR, MAPK signals and the above profibrotic molecules, but amplified the increase in AT1 level stimulated by aldosterone (10(-6)M). Eplerenone 19-29 nuclear receptor subfamily 3 group C member 2 Homo sapiens 79-81 24231917-10 2013 Mineralocorticoid receptor antagonists like spironolactone or eplerenone have been shown to be efficacious in patients with RHTN, heart failure, chronic kidney disease, and primary aldosteronism. Eplerenone 62-72 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 24133375-1 2013 Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. Eplerenone 171-181 nuclear receptor subfamily 3 group C member 2 Homo sapiens 218-220 23881669-1 2013 Eplerenone (Inspra ) is a selective mineralocorticoid receptor antagonist (MRA). Eplerenone 0-10 nuclear receptor subfamily 3 group C member 2 Homo sapiens 36-62 22717248-1 2012 BACKGROUND: In animal models, aldosterone has adverse cardiac and vascular effects independent of blood pressure, and these are ameliorated by spironolactone or eplerenone (mineralocorticoid receptor antagonists). Eplerenone 161-171 nuclear receptor subfamily 3 group C member 2 Homo sapiens 173-199 23456826-6 2013 Our results showed that ALD could significantly activate the Rho kinase in HK-2 cells, while in the presence of mineralocorticoid receptor (MR) antagonist eplerenone and Rho kinase inhibitor Y27632, the Rho kinase protein expression were almost completely prevented. Eplerenone 155-165 nuclear receptor subfamily 3 group C member 2 Homo sapiens 112-138 23456826-6 2013 Our results showed that ALD could significantly activate the Rho kinase in HK-2 cells, while in the presence of mineralocorticoid receptor (MR) antagonist eplerenone and Rho kinase inhibitor Y27632, the Rho kinase protein expression were almost completely prevented. Eplerenone 155-165 nuclear receptor subfamily 3 group C member 2 Homo sapiens 140-142 23333184-3 2013 Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, prevent some of these maladaptive effects on the cardiovascular system and have proven to be a highly efficacious pharmacological therapy. Eplerenone 74-84 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 23171954-4 2013 In Japan, both the selective MR antagonist eplerenone and the non-selective MR antagonist spironolactone are indicated for the treatment of hypertension. Eplerenone 43-53 nuclear receptor subfamily 3 group C member 2 Homo sapiens 29-31 23006216-0 2013 Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males. Eplerenone 57-67 nuclear receptor subfamily 3 group C member 2 Homo sapiens 19-45 23023156-0 2012 Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. Eplerenone 35-45 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 23023156-4 2012 Using this pain model, the authors applied the MR antagonist eplerenone locally to the inflamed DRG. Eplerenone 61-71 nuclear receptor subfamily 3 group C member 2 Homo sapiens 47-49 23661677-8 2013 In contrast, the mineralocorticoid receptor antagonists, spironolactone or eplerenone, significantly attenuated DOCA and salt- or aldosterone and salt-induced aortic aneurysm. Eplerenone 75-85 nuclear receptor subfamily 3 group C member 2 Homo sapiens 17-43 23740451-2 2013 AIM: To present a 38 year-old woman with an impressive improvement of CSCR following MR antagonist eplerenone administration. Eplerenone 99-109 nuclear receptor subfamily 3 group C member 2 Homo sapiens 85-87 23349535-11 2013 Prevention or restoration of these changes via blockade of aldosterone action in the vascular wall with MR antagonists (i.e., spironolactone, eplerenone) may therefore account for the clinical benefit of these compounds in obese and diabetic patients with cardiovascular disease. Eplerenone 142-152 nuclear receptor subfamily 3 group C member 2 Homo sapiens 104-106 22778046-1 2012 Randomized controlled trials demonstrate the efficacy of aldosterone receptor antagonists (spironolactone and eplerenone) as a useful pharmacologic intervention specifically in patients with New York Heart Association (NYHA) class III and IV heart failure, in patients with an ejection fraction <40% after myocardial infarction, and most recently in patients with mildly symptomatic heart failure. Eplerenone 110-120 nuclear receptor subfamily 3 group C member 2 Homo sapiens 57-77 22608985-6 2012 Mineralocorticoid receptor antagonist eplerenone and p66Shc short interfering RNA prevented Aldo-induced MtD and EMT, as evidenced by downregulation of alpha-smooth muscle actin and upregulation of E-cadherin. Eplerenone 38-48 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 22791416-3 2012 Use of the currently marketed MR antagonists spironolactone and eplerenone is restricted, however, due to a lack of selectivity in spironolactone and the lower potency and efficacy of eplerenone. Eplerenone 64-74 nuclear receptor subfamily 3 group C member 2 Homo sapiens 30-32 22791416-3 2012 Use of the currently marketed MR antagonists spironolactone and eplerenone is restricted, however, due to a lack of selectivity in spironolactone and the lower potency and efficacy of eplerenone. Eplerenone 184-194 nuclear receptor subfamily 3 group C member 2 Homo sapiens 30-32 22411952-5 2012 Mineralocorticoid receptor antagonists, such as spironolactone and eplerenone that are used to treat side effects related to mineralocorticoid excess, can also bind to and activate signaling through wild-type or mutant AR. Eplerenone 67-77 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 22684104-9 2012 To translate these findings, we treated 2 patients with chronic nonresolved CSCR with oral eplerenone, a specific MR antagonist, for 5 weeks, and observed impressive and rapid resolution of retinal detachment and choroidal vasodilation as well as improved visual acuity. Eplerenone 91-101 nuclear receptor subfamily 3 group C member 2 Homo sapiens 114-116 22205191-0 2012 Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Eplerenone 35-45 nuclear receptor subfamily 3 group C member 2 Homo sapiens 0-26 22205191-2 2012 The purpose of this study was to evaluate the effects of the selective mineralocorticoid receptor blocker, eplerenone, on endothelial function and ROCK activity in patients with hypertension. Eplerenone 107-117 nuclear receptor subfamily 3 group C member 2 Homo sapiens 71-97 22032706-2 2011 OBJECTIVES: The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n = 6,080) and whether this was associated with eplerenone"s beneficial effects on cardiovascular outcomes. Eplerenone 124-134 nuclear receptor subfamily 3 group C member 2 Homo sapiens 138-164 22214629-6 2012 Although eplerenone has an advantage over spironolactone for its selective affinity for the aldosterone receptor, the efficacy and safety of eplerenone for GS is little understood. Eplerenone 9-19 nuclear receptor subfamily 3 group C member 2 Homo sapiens 92-112 22032706-10 2011 CONCLUSIONS: Eplerenone"s beneficial effects on long-term survival and cardiovascular outcomes are independent from early potassium-sparing or diuretic effects, suggesting that mineralocorticoid receptor antagonism provides cardiovascular protection beyond its diuretic and potassium-sparing properties. Eplerenone 13-23 nuclear receptor subfamily 3 group C member 2 Homo sapiens 177-203 21144811-6 2011 Several clinical studies now report benefit and safety when using spironolactone or eplerenone, the currently available mineralocorticoid receptor antagonists, in patients with kidney diseases. Eplerenone 84-94 nuclear receptor subfamily 3 group C member 2 Homo sapiens 120-146 21896143-2 2011 Newer, more selective MR antagonists (eg, eplerenone) have fewer of the progestational and antiandrogenic effects than spironolactone, enhancing tolerability and potentially improving adherence to therapy. Eplerenone 42-52 nuclear receptor subfamily 3 group C member 2 Homo sapiens 22-24